Search alternatives:
significant linear » significant clinical (Expand Search), significant level (Expand Search), significant gender (Expand Search)
level increased » levels increased (Expand Search), levels decreased (Expand Search)
linear decrease » linear increase (Expand Search)
level decrease » levels decreased (Expand Search), level disease (Expand Search), teer decrease (Expand Search)
Showing 101 - 120 results of 87,519 for search '(( significant ((level decrease) OR (level increased)) ) OR ( significant linear decrease ))', query time: 1.24s Refine Results
  1. 101
    Overexpression of Runx1 increases osteoblasts and decreases adipocytes and osteoblast markers levels <i>in vitro</i>.

    Overexpression of Runx1 increases osteoblasts and decreases adipocytes and osteoblast markers levels <i>in vitro</i>. by Chen-Yi Tang (3619124)

    Published 2021
    Save to List
    Saved in:
  2. 102
    Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases.

    Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

    Published 2023
    Save to List
    Saved in:
  3. 103
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 104
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 105
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 106
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 107
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 108
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 109
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 110
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 111
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 112
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 113
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 114
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 115
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 116
    Decreasing <i>abi</i> RNA levels in all FCs results in increased BC migration speed.

    Decreasing <i>abi</i> RNA levels in all FCs results in increased BC migration speed. by Ester Molina López (16462735)

    Published 2023
    Save to List
    Saved in:
  17. 117
    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus the concentration of dissolved oxygen (DO) in milligrams per liter (mg/L).

    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus the concentration o... by Seth H. Frisbie (7821866)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 118
    Linear regression model with MBI score.

    Linear regression model with MBI score. by Nadia Yanet Cortés-Álvarez (18611445)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 119
    Levels of cytokines and chemokines over time.

    Levels of cytokines and chemokines over time. by Beate Grüner (301524)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  20. 120
    Predictors of higher-level coronary hyperemic DPV increase after PCI (>50% increase).

    Predictors of higher-level coronary hyperemic DPV increase after PCI (>50% increase). by Eisuke Usui (12111855)

    Published 2024
    Save to List
    Saved in:

Search Tools: